 Eric Hink
Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Orbit | 7 | 2024 | 52 | 1.770 |
Why?
| | Eyelids | 7 | 2024 | 27 | 1.750 |
Why?
| | Eyelid Diseases | 5 | 2024 | 17 | 1.690 |
Why?
| | Orbital Fractures | 4 | 2017 | 8 | 1.130 |
Why?
| | Surgical Mesh | 1 | 2024 | 40 | 0.880 |
Why?
| | Titanium | 1 | 2024 | 72 | 0.850 |
Why?
| | Tetralogy of Fallot | 1 | 2024 | 81 | 0.840 |
Why?
| | Oculomotor Muscles | 3 | 2017 | 38 | 0.810 |
Why?
| | Sarcoma, Kaposi | 1 | 2022 | 68 | 0.790 |
Why?
| | Eye Infections, Bacterial | 4 | 2015 | 24 | 0.760 |
Why?
| | Ophthalmologic Surgical Procedures | 7 | 2015 | 55 | 0.730 |
Why?
| | Eye Infections, Fungal | 3 | 2017 | 6 | 0.700 |
Why?
| | Orbital Diseases | 2 | 2017 | 24 | 0.690 |
Why?
| | Down Syndrome | 1 | 2024 | 335 | 0.640 |
Why?
| | Skull Neoplasms | 1 | 2017 | 22 | 0.560 |
Why?
| | Sphenoid Bone | 1 | 2017 | 15 | 0.560 |
Why?
| | Meningioma | 1 | 2017 | 76 | 0.520 |
Why?
| | Blepharophimosis | 1 | 2013 | 3 | 0.440 |
Why?
| | Candidiasis | 1 | 2013 | 51 | 0.430 |
Why?
| | Eye Injuries | 2 | 2014 | 42 | 0.410 |
Why?
| | Prostheses and Implants | 3 | 2024 | 135 | 0.400 |
Why?
| | Orbital Cellulitis | 3 | 2015 | 14 | 0.360 |
Why?
| | Conjunctiva | 1 | 2011 | 50 | 0.360 |
Why?
| | Surgical Wound Infection | 1 | 2013 | 246 | 0.360 |
Why?
| | Golf | 1 | 2008 | 4 | 0.310 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2013 | 328 | 0.310 |
Why?
| | Tomography, X-Ray Computed | 9 | 2017 | 2272 | 0.300 |
Why?
| | Inflammation | 1 | 2017 | 2464 | 0.270 |
Why?
| | Humans | 31 | 2024 | 114045 | 0.240 |
Why?
| | Child, Preschool | 10 | 2017 | 9114 | 0.240 |
Why?
| | Alprostadil | 1 | 2024 | 31 | 0.220 |
Why?
| | Orbital Neoplasms | 3 | 2015 | 19 | 0.220 |
Why?
| | Surgical Flaps | 3 | 2015 | 121 | 0.210 |
Why?
| | Syndrome | 1 | 2024 | 330 | 0.210 |
Why?
| | Eye Burns | 1 | 2022 | 11 | 0.210 |
Why?
| | Compartment Syndromes | 1 | 2022 | 29 | 0.200 |
Why?
| | Dacryocystorhinostomy | 2 | 2015 | 9 | 0.200 |
Why?
| | Optic Nerve | 1 | 2022 | 65 | 0.200 |
Why?
| | Eye | 1 | 2022 | 97 | 0.190 |
Why?
| | Injections | 1 | 2022 | 160 | 0.190 |
Why?
| | Adolescent | 13 | 2017 | 17800 | 0.180 |
Why?
| | Mucormycosis | 2 | 2017 | 20 | 0.170 |
Why?
| | Cicatrix | 2 | 2017 | 49 | 0.170 |
Why?
| | Retrospective Studies | 10 | 2022 | 12521 | 0.170 |
Why?
| | Male | 16 | 2024 | 55396 | 0.170 |
Why?
| | Child | 11 | 2017 | 18401 | 0.160 |
Why?
| | Eye Pain | 2 | 2017 | 7 | 0.160 |
Why?
| | Neoplasm Invasiveness | 2 | 2017 | 438 | 0.150 |
Why?
| | Critical Care | 1 | 2022 | 472 | 0.150 |
Why?
| | Mucocele | 1 | 2017 | 11 | 0.140 |
Why?
| | Mucorales | 1 | 2017 | 1 | 0.140 |
Why?
| | Paranasal Sinus Diseases | 1 | 2017 | 14 | 0.140 |
Why?
| | Visual Acuity | 4 | 2017 | 272 | 0.140 |
Why?
| | Nose Diseases | 1 | 2017 | 10 | 0.140 |
Why?
| | Graves Ophthalmopathy | 1 | 2017 | 8 | 0.140 |
Why?
| | Floods | 1 | 2017 | 14 | 0.140 |
Why?
| | Amnion | 1 | 2017 | 24 | 0.140 |
Why?
| | Conjunctival Diseases | 1 | 2017 | 17 | 0.140 |
Why?
| | Receptor, IGF Type 1 | 1 | 2017 | 58 | 0.140 |
Why?
| | Corneal Diseases | 1 | 2017 | 32 | 0.140 |
Why?
| | Soft Tissue Injuries | 1 | 2017 | 31 | 0.140 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2017 | 34 | 0.140 |
Why?
| | Infant | 6 | 2017 | 7943 | 0.140 |
Why?
| | Endoscopy | 2 | 2017 | 245 | 0.140 |
Why?
| | Craniotomy | 1 | 2017 | 68 | 0.140 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1331 | 0.130 |
Why?
| | Streptococcal Infections | 3 | 2015 | 127 | 0.130 |
Why?
| | Female | 17 | 2017 | 59324 | 0.130 |
Why?
| | Vision Disorders | 1 | 2017 | 127 | 0.130 |
Why?
| | Disasters | 1 | 2017 | 87 | 0.130 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2015 | 4 | 0.130 |
Why?
| | Cavernous Sinus Thrombosis | 1 | 2015 | 9 | 0.130 |
Why?
| | Lacrimal Apparatus | 1 | 2015 | 7 | 0.130 |
Why?
| | Polyglycolic Acid | 1 | 2015 | 43 | 0.120 |
Why?
| | Adult | 10 | 2022 | 30375 | 0.120 |
Why?
| | Absorbable Implants | 1 | 2015 | 33 | 0.120 |
Why?
| | Biopsy | 2 | 2017 | 1024 | 0.120 |
Why?
| | Immunologic Factors | 1 | 2017 | 217 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 5 | 2017 | 3039 | 0.120 |
Why?
| | Prednisone | 1 | 2015 | 229 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2014 | 4392 | 0.120 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2014 | 6 | 0.110 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2015 | 144 | 0.110 |
Why?
| | Facial Paralysis | 1 | 2014 | 17 | 0.110 |
Why?
| | Osteotomy | 1 | 2015 | 143 | 0.110 |
Why?
| | Exophthalmos | 2 | 2017 | 16 | 0.110 |
Why?
| | Platinum | 1 | 2014 | 38 | 0.110 |
Why?
| | School Admission Criteria | 1 | 2013 | 20 | 0.110 |
Why?
| | Lactic Acid | 1 | 2015 | 272 | 0.110 |
Why?
| | Surgery, Plastic | 1 | 2013 | 24 | 0.110 |
Why?
| | Silicone Elastomers | 1 | 2013 | 7 | 0.110 |
Why?
| | Mycobacterium chelonae | 1 | 2013 | 8 | 0.110 |
Why?
| | Analgesics | 1 | 2015 | 156 | 0.110 |
Why?
| | Jaw Fractures | 1 | 2013 | 2 | 0.110 |
Why?
| | Middle Aged | 9 | 2017 | 26605 | 0.110 |
Why?
| | Pain, Postoperative | 1 | 2015 | 190 | 0.110 |
Why?
| | C-Reactive Protein | 1 | 2015 | 362 | 0.110 |
Why?
| | Aged, 80 and over | 6 | 2015 | 6306 | 0.110 |
Why?
| | Sinusitis | 1 | 2015 | 174 | 0.110 |
Why?
| | Skull Fractures | 1 | 2013 | 28 | 0.110 |
Why?
| | Facial Bones | 1 | 2013 | 29 | 0.110 |
Why?
| | Bites and Stings | 1 | 2013 | 30 | 0.100 |
Why?
| | Gold | 1 | 2014 | 102 | 0.100 |
Why?
| | Eye Injuries, Penetrating | 1 | 2013 | 16 | 0.100 |
Why?
| | Eye Foreign Bodies | 1 | 2013 | 23 | 0.100 |
Why?
| | Suture Techniques | 1 | 2013 | 115 | 0.100 |
Why?
| | Ophthalmology | 1 | 2013 | 75 | 0.100 |
Why?
| | Craniocerebral Trauma | 1 | 2014 | 133 | 0.100 |
Why?
| | Dogs | 1 | 2013 | 331 | 0.100 |
Why?
| | Adenoma | 1 | 2014 | 187 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2015 | 526 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1257 | 0.090 |
Why?
| | Fellowships and Scholarships | 1 | 2013 | 224 | 0.090 |
Why?
| | Fracture Fixation, Internal | 1 | 2013 | 194 | 0.090 |
Why?
| | Endophthalmitis | 1 | 2010 | 25 | 0.090 |
Why?
| | Retinal Neoplasms | 1 | 2010 | 21 | 0.090 |
Why?
| | Retinoblastoma | 1 | 2010 | 27 | 0.090 |
Why?
| | Intraoperative Complications | 1 | 2011 | 120 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 366 | 0.080 |
Why?
| | Streptococcus agalactiae | 1 | 2010 | 81 | 0.080 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 2010 | 132 | 0.080 |
Why?
| | Aged | 7 | 2017 | 18969 | 0.080 |
Why?
| | Blindness | 1 | 2008 | 36 | 0.070 |
Why?
| | Burkitt Lymphoma | 1 | 2008 | 52 | 0.070 |
Why?
| | Decision Making | 1 | 2014 | 760 | 0.070 |
Why?
| | Age Factors | 1 | 2014 | 2885 | 0.070 |
Why?
| | Sweat Gland Neoplasms | 1 | 2006 | 5 | 0.070 |
Why?
| | Eyelid Neoplasms | 1 | 2006 | 7 | 0.060 |
Why?
| | Biomarkers | 1 | 2015 | 3397 | 0.060 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2006 | 61 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2013 | 2122 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2017 | 9049 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2017 | 1656 | 0.050 |
Why?
| | Anti-Bacterial Agents | 3 | 2015 | 1471 | 0.050 |
Why?
| | Staphylococcal Infections | 2 | 2015 | 340 | 0.050 |
Why?
| | Young Adult | 2 | 2017 | 10444 | 0.040 |
Why?
| | Intraocular Pressure | 1 | 2022 | 275 | 0.040 |
Why?
| | Prospective Studies | 3 | 2015 | 6195 | 0.040 |
Why?
| | Diplopia | 1 | 2017 | 15 | 0.040 |
Why?
| | Ocular Motility Disorders | 1 | 2017 | 25 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 69 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 2017 | 92 | 0.030 |
Why?
| | Nasolacrimal Duct | 1 | 2015 | 5 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 192 | 0.030 |
Why?
| | Diabetes Complications | 1 | 2017 | 208 | 0.030 |
Why?
| | Blepharoplasty | 1 | 2015 | 5 | 0.030 |
Why?
| | Pregabalin | 1 | 2015 | 9 | 0.030 |
Why?
| | Perioperative Period | 1 | 2015 | 47 | 0.030 |
Why?
| | Bone Nails | 1 | 2015 | 58 | 0.030 |
Why?
| | Hyperglycemia | 1 | 2017 | 292 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2015 | 141 | 0.030 |
Why?
| | Administration, Oral | 1 | 2015 | 725 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 192 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 660 | 0.030 |
Why?
| | Pain Measurement | 1 | 2015 | 441 | 0.030 |
Why?
| | ROC Curve | 1 | 2014 | 441 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1829 | 0.020 |
Why?
| | Pain Management | 1 | 2015 | 285 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2014 | 5038 | 0.020 |
Why?
| | Foreign Bodies | 1 | 2013 | 93 | 0.020 |
Why?
| | Athletic Injuries | 1 | 2017 | 456 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2314 | 0.020 |
Why?
| | Length of Stay | 1 | 2015 | 957 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1218 | 0.020 |
Why?
| | Microscopy, Acoustic | 1 | 2010 | 8 | 0.020 |
Why?
| | Eye Enucleation | 1 | 2010 | 10 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1117 | 0.020 |
Why?
| | Etoposide | 1 | 2008 | 149 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2008 | 214 | 0.020 |
Why?
| | Maxilla | 1 | 2007 | 29 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4090 | 0.020 |
Why?
| | Methotrexate | 1 | 2008 | 227 | 0.020 |
Why?
| | Doxorubicin | 1 | 2008 | 286 | 0.020 |
Why?
| | Quality of Life | 1 | 2017 | 2343 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3315 | 0.020 |
Why?
| | Mohs Surgery | 1 | 2006 | 24 | 0.020 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2006 | 182 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 4595 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1356 | 0.010 |
Why?
| | United States | 1 | 2013 | 12137 | 0.010 |
Why?
| | Animals | 1 | 2013 | 31565 | 0.010 |
Why?
|
|
Hink's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|